an adaptor protein involved in innate immunity against invading pathogens. Associates with TLR3 and TLR4 (through TICAM2) to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TICAM1 recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. Interacts with the TIR domain of TLR3. Interacts with AZI2, TBK1, IRF3 and IRF7. Interacts with TICAM2 in TLR4 recruitment. Interaction with PIAS4 inhibits the TICAM1-induced NF-kappa-B, IRF and IFNB1 activation. Interacts with IKBKB and IKBKE. Interaction with SARM1 blocks TICAM1-dependent transcription factor activation. Interacts with TRAF3. Interacts with TRAFD1. Note: This description may include information from UniProtKB.
Protein type: Apoptosis; Adaptor/scaffold
Cellular Component: endosome membrane; cytosol
Molecular Function: signal transducer activity; protein binding; protein kinase binding
Biological Process: I-kappaB kinase/NF-kappaB cascade; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of nitric oxide biosynthetic process; positive regulation of protein binding; MyD88-independent toll-like receptor signaling pathway; regulation of protein homodimerization activity; positive regulation of interleukin-6 production; toll-like receptor 3 signaling pathway; positive regulation of tumor necrosis factor production; activation of NF-kappaB transcription factor; positive regulation of chemokine biosynthetic process; response to exogenous dsRNA; positive regulation of protein ubiquitination; positive regulation of interferon-beta biosynthetic process; macrophage activation during immune response; lipopolysaccharide-mediated signaling pathway; positive regulation of interferon type I production; positive regulation of B cell proliferation; toll-like receptor signaling pathway; innate immune response; inflammatory response; defense response to virus; toll-like receptor 4 signaling pathway
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.